relief drugs, is enrolling patients in a Phase II clinical
trial of inhaled oxytocin to treat chronic migraine. Trigemina's oxytocin
product, known as T1-001 (no doubt to be renamed to something lyrical if it
comes to market), has already shown promising results in preliminary studies,
the company says.
This
use makes perfect sense: Oxytocin is a general analgesic (pain reducer), and it
also contributes to relaxation and healing.
It's notable that
Trigemina specializes in inhalant drugs, and it has a proprietary
formulation of oxytocin. Without some market angle, there's little
incentive for companies to develop oxytocin-based drugs.
If and when this comes to market, I can see it being prescribed off-label for all kinds of things, including persistent genital arousal disorder (PGAD) and fibromyalgia.
